Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-04-20

Study Completion Date

2009-06-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the absorption of dietary phosphorus following a single dose with lanthanum carbonate (1000mg) and a single dose of sevelamer carbonate (2400mg).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults

NCT00880750

End Stage Renal Disease

COMPLETED PHASE1

Fosrenol and Phosphorus Balance - Lanthanum Carbonate

NCT01581996

Chronic Kidney Failure End-stage Renal Disease Disorders Associated With Peritoneal Dialysis

COMPLETED NA

Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease

NCT00160121

Kidney Failure, Chronic

COMPLETED PHASE4

Head to Head Study Against Sevelamer Hydrochloride

NCT00441545

Chronic Kidney Disease, Stage 5

COMPLETED PHASE3

Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)

NCT00567723

Hyperphosphatemia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Failure, Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Meal + Lanthanum

Group Type EXPERIMENTAL

Lanthanum Carbonate

Intervention Type DRUG

1 x 1000mg tablet

Meal + Sevelamer

Group Type ACTIVE_COMPARATOR

Sevelamer

Intervention Type DRUG

3 x 800mg tablets

Meal Only

Group Type NO_INTERVENTION

No interventions assigned to this group

Fasting

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lanthanum Carbonate

1 x 1000mg tablet

Intervention Type DRUG

Sevelamer

3 x 800mg tablets

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fosrenol Renvela

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ability to provide informed consent to participate in the study.
* Healthy volunteers, age 19-45 inclusive.
* Subject must be willing to comply with applicable contraceptive requirements of the protocol
* Female subjects must have a negative pregnancy test
* Satisfactory medical assessment with no clinically significant or relevant abnormalities in medical history, physical examination, vital signs, ECG and laboratory evaluation.
* Body Mass Index (BMI) between 20.0 and 29.9kg/m² inclusive.
* Serum 1.25 dihydroxy vitamin D3 \>30pg/mL.
* Ability to chew or swallow a dose of the investigational products and mannitol solution as prescribed in the protocol.
* Ability and willingness to fast for up to 24 hours.

Exclusion Criteria

* Current or recurrent disease that could affect the action, absorption or disposition of the investigational products utilized in this study, or could affect clinical or laboratory assessments.
* Current or relevant previous history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or study procedures.
* Significant illness within 2 weeks of the first dose of investigational product.
* Current use of any medication with the exception of hormonal replacement therapy or hormonal contraceptives within 14 days of first dose of investigational product.
* Known or suspected intolerance or hypersensitivity to the investigational product(s) or mannitol solution, closely related compounds or any of the stated ingredients.
* History of alcohol or other substance abuse within the last year.
* A positive screen for alcohol or drugs of abuse.
* Male subjects who consume more than 21 units of alcohol per week or three units per day. Female subjects who consume more than 14 units of alcohol per week or two units per day.
* A positive human immunodeficiency virus (HIV) antibody screen, Hepatitis B surface antigen (HBsAg) or Hepatitis C virus (HCV) antibody screen.
* Use of tobacco in any form or other nicotine-containing products in any form. Ex-users must report that they have stopped using tobacco for at least 30 days prior to receiving the first dose of investigational product.
* Routine consumption of more than two units of caffeine per day or subjects who experience caffeine withdrawal headaches.
* Donation of blood or blood products within 60 days prior to receiving the first dose of investigational product.
* Use of another investigational product within 30 days prior to receiving the first dose of investigational product or active enrolment in another drug or vaccine clinical study.
* An inability to follow a standardized diet and/or meal schedule, as required during the study.
* Substantial changes in eating habits within 30 days prior to receiving the first dose of investigational product, as assessed by the Investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes